Favaretto, A., Grossi, F., Morabito, A. and Ravasio, R. (2017) “Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations: Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR”, Global and Regional Health Technology Assessment, 4(1), pp. 187–196. doi: 10.33393/grhta.2017.394.